Teva Submits BLA to FDA for Migraine Candidate Fremanezumab

A generic image of a pen on top of a stock chart.
Credit: Shutterstock photo

Teva Pharmaceutical Industries LtdTEVA announced the submission of a biologics license application ("BLA") to the FDA seeking approval for its monoclonal antibody candidate, fremanezumab, as a preventive treatment for migraine.

The BLA submission was supported by positive data from two phase III studies under HALO program, which evaluated the candidate in patients with episodic migraine ("EM") and chronic migraine ("CM").

Fremanezumab was subcutaneously administered once a month for two months (quarterly dose regimen), either in high (675mg) or low doses (225 mg, monthly dose regimen) in the study on CM patients. The data demonstrated statistically significant reduction in the number of monthly headache days when treated with fremanezumabcompared to a placebo. The study also met its secondary endpoints and showed significant improvement over placebo.

Data from the study on EM patients showed that patients who were treated with monthly as well as quarterly dosing regimens of fremanezumab experienced clinically and statistically significant improvements in monthly average number of migraine days and 12 pre-specified analyses.

Given the limited treatment options, fremanezumab represents significant commercial potential. According to Teva's press release, more than a billion people suffer from migraine across the world including 38 million in the United States.

We remind investors that the BLA from Amgen, Inc. AMGN and partner Novartis AG NVS for approval of their CGRP receptor, erenumab, for the prevention of migraine was accepted by the FDA in July. Eli Lilly & Company LLY is also planning to file for FDA approval of its investigational migraine drug, galcanezumab, in the second half of the year.

Today's Stocks from Zacks' Hottest Strategies

It's hard to believe, even for us at Zacks. But while the market gained +18.8% from 2016 - Q1 2017, our top stock-picking screens have returned +157.0%, +128.0%, +97.8%, +94.7%, and +90.2% respectively.

And this outperformance has not just been a recent phenomenon. Over the years it has been remarkably consistent. From 2000 - Q1 2017, the composite yearly average gain for these strategies has beaten the market more than 11X over. Maybe even more remarkable is the fact that we're willing to share their latest stocks with you without cost or obligation.

See Them Free>>

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

Eli Lilly and Company (LLY): Free Stock Analysis Report

Novartis AG (NVS): Free Stock Analysis Report

Amgen Inc. (AMGN): Free Stock Analysis Report

Teva Pharmaceutical Industries Limited (TEVA): Free Stock Analysis Report

To read this article on click here.

Zacks Investment Research

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story


Other Topics


Latest Markets Videos


Zacks is the leading investment research firm focusing on stock research, analysis and recommendations. In 1978, our founder discovered the power of earnings estimate revisions to enable profitable investment decisions. Today, that discovery is still the heart of the Zacks Rank. A wealth of resources for individual investors is available at

Learn More